Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB) or metastatic (stage IV) non-squamous NSCLC * Non-squamous histologic type * At least one and no more than two previous chemotherapy regimens for advanced or metastatic NSCLC * Measurable disease, defined as at least 1 bidimensionally measurable lesion ≥ 20 X 10 mm. * Age ≥ 18 years * Performance status (WHO) 0-2 * Life expectancy of at least 12 weeks * Adequate bone marrow (ANC ≥ 1,500/mm3, PLT ≥ 100,000/mm3, Hgb ≥ 9 g/dL), liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 2.5 upper normal limit in the absence of liver metastases or ≤ 5 upper normal limit in the presence of liver metastases), and renal function (Creatinine ≤ 1,5 upper normal limit) * Patients must be able to understand the nature of this study * Written informed consent Exclusion Criteria: * Previous therapy with paclitaxel in combination with carboplatin * Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer * Pregnant or lactating women * Any serious, uncontrolled comorbidity on the investigator's judgment * Uncontrolled infection * Any sustained chronic toxicity \> grade 2 according to the NCI CTCAE (version 3.0) * Symptomatic neuropathy \> grade 2 according to the NCI CTCAE (version 3.0) * Brain metastases, except if radiated and asymptomatic * Radiotherapy within the previous 4 weeks * Previous radiotherapy to the only measurable lesion * Proteinuria ≥ 500 mgr of protein daily * Hemoptysis \> 10 cc per event * Clinically significant hematemesis * Centrally located lesion or in contact with major vessels * Pulmonary lesion with cavitation * Documented hemorrhagic diathesis or coagulation disorder * Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, unstable angina, LVEF \< normal, ventricular arrhythmia, uncontrolled hypertension) * Thrombotic event within the previous 6 months * Concurrent use of aspirin \> 325 mgr daily, low molecular weight heparin in therapeutic dose, warfarin or acenocoumarol, non-steroid anti-inflammatory agents * Concurrent treatment with other anti-cancer drug * Major surgical procedure within the previous 4 weeks